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Abstract 
Purpose: To assess the protective effect of Qizhuyigan capsules containing an herbal mixture on liver 
function in a mouse model of immunological liver injury and to explore the mechanism of action. 
Methods: One hundred and twenty mice were randomly divided into four groups: control, test, 
bifendate, and Qizhuyigan. Immunological liver injury was induced in all groups except the control 
group. Mice in the control group and the test group were gavaged with 2.5 g/kg tap water, mice in the 
bifendate group were gavaged with 12 mg/kg bifendate in water, and mice in the Qizhuyigan group were 
gavaged with 1,000 mg/kg of an aqueous solution containing the contents of a Qizhuyigan capsule. The 
gavage continued for 10 days. Changes in liver function-related indices, such as the levels of alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), malonaldehyde (MDA), superoxide 
dismutase (SOD), tumor necrosis factor α (TNF-α), and interleukin 6 (IL-6), were assessed. 
Results: Compared with the test and bifendate groups, the Qizhuyigan group exhibited lower serum 
ALT (98.3 U/L ± 8.7 U/L vs. 224.7 U/L ± 18.4 U/L vs. 132.8 U/L ± 9.4 U/L); AST (165.5 U/L ± 12.1 U/L 
vs. 362.6 U/L ± 16.6 U/L vs. 224.6 U/L ± 12.2 U/L); and MDA levels (12.7 ± 2 μmol/L vs. 31.3 ± 6.60 
μmol/L vs. 14.4 ± 2.3 μmol/L); a higher SOD level; and reduced TNF-α and IL-6 levels. The differences 
of the above indices had statistical significance (p < 0.05). 
Conclusion: Qizhuyigan exerted a protective effect in a mouse model of immunological liver injury. 
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Viral hepatitis has various routes of infection, and 
the population suffering from viral hepatitis is 
widespread. China has the largest population of 
hepatitis B patients worldwide and the morbidity 
associated with hepatitis C is increasing annually 
[1]. Persistent infection and repeated viral attacks 
are important factors in liver cirrhosis and 
primary hepatic carcinoma (PHC) [2]. 
 
Currently, Western medicine usually treats viral 
hepatitis by inhibiting virus replication, protecting 
hepatocytes, reducing transaminases, and 
improving immune function. Drugs such as 
nucleosides and interferon have good short-term 
curative effects, but their long-term effects are 
unsatisfactory. Moreover, the high medical 
expenses, the severe toxic side effects of drugs, 
and viral drug resistance, are problematic [3,4]. It 
would be very useful to identify a drug that 
inhibits acute liver immunoreaction and lipid 
peroxidation, removes free radicals, reduces the 
levels of cytotoxic factors, and modulates liver 
metabolism [5,6]. 
 
Schemes based on traditional Chinese medicine 
have long been used to treat liver disease, and 
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valuable experience has been accumulated. 
Recently, the pharmacological mechanisms and 
the clinical medicinal value of some Chinese 
herbal medicines have been clarified, and their 
lower costs, fewer toxic effects, and reliable long-
term curative effects make them worthy of study 
[7]. 
 
Qizhuyigan capsule contains seven traditional 
Chinese medicinal materials, including the root of 
red-rooted salvia, felwort, white atractylodes 
rhizome, Astragalus membranaceus, and radix 
isatidis. The preparation can eliminate damp-
heat, and regulates the liver and spleen. The 
capsule is used clinically to treat various types of 
chronic hepatitis, and has good curative effects, 
but its mechanism of action has not been 
determined [8]. 
 
The study mainly explored the mechanism of 
action of Qizhuyigan on liver function in a mouse 
model of immunological liver injury to provide a 
theoretical foundation for the treatment of 
immunological liver injury and offer an 





Drugs and reagents 
 
Qizhuyigan capsules formulated from 15 g of the 
root of red-rooted salvia, 15 g rough gentian, 15 
g Rhizoma Atractylodis Macrocephalae, 15 g 
Astragalus membranaceus, 12 g Radix isatidis, 
10 g Semen brassicae, and 6 g Curcuma 
zedoary were obtained from the Binzhou 
People’s Hospital. Bifendate pills (batch number: 
2014122081) were purchased from Guangzhou 
Baiyun Moutain Xingqun Pharmacy Co., Ltd. 
(China), malondialdehyde (MDA), superoxide 
dismutase (SOD), allophanamide (Shanghai 
Hongshun Biotech. Co., Ltd., China), tumour 
necrosis factor-α (TNF-α) enzyme-linked 
immunosorbent assay (ELISA), and interleukin 6 
(IL-6) kits (Beijing Biolab Science and 
Technology Ltd., China) were also purchased. 
 
Animals and instruments 
 
One hundred and twenty male mice (body weight 
range 18 – 22 g) were obtained from the 
Experimental Animal Centre of Binzhou Medical 
College, Shandong, China, and were acclimated 
for 7 d in the Binzhou People’s Hospital, 
Shandong, China. Instruments used included an 
AU5800 automatic biochemical analyser 
(Beckman Coulter, Inc., USA), a TG18G-II high-
speed centrifuge (Shanghai Yanqi Biotechnology 
Co., Ltd., China), an RX-MBY enzyme-labelling 
instrument (Beijing Ruixi 
Science and Technology Ltd., China), a UV-765 
ultraviolet and visible spectrophotometer 
(Shanghai Junke Biotech. Co., Ltd., China), and 
an AUW120D analytical balance (Shimadzu Inc., 
Japan).  
 
Grouping and modelling 
 
The 120 mice were divided randomly into control, 
test, bifendate, and Qizhuyigan groups. The 
model used was reported previously [9]. 
Specifically, except for the control group, the 
other groups were gavaged with tap water at 2.5 
g/kg. Mice in the bifendate group were gavaged 
with 12 mg/kg of the drug, and mice in the 
Qizhuyigan group were gavaged with water 
containing the contents of a Qizhuyigan capsule 
(1,000 mg/kg), for 10 days. On the last day of the 
experiment, all mice except those in the blank 
control group were injected intravenously with 
lipopolysaccharides (0.4 mg/kg) through the tail 
vein after the last dosing. Furthermore, each 
mouse was fixed with a fixator, with its tail 
outside the fixators. The tail was repeatedly 
wiped with of 75 % (v/v) ethyl alcohol. The tail 
vein was punctured with a syringe at an angle of 
30° and a white line was seen along the vein. 
The absence of resistance during drug injection 
indicated that the tip of the needle had 
penetrated the vein, and residual drug was then 
injected continuously. Then, the needle was 
removed and the injection site was pressed with 
a cotton swab to stop the bleeding. Mice were 
provided with water, but no food, after the 
injection. They were assessed 12 h after the 
injection. 
 
This study was approved by the Medical Ethics 
Committee of Binzhou People’s Hospital 
(approval no. ZXQ20160115BZ) and followed the 
protocols set out in the Declaration of Helsinki 
[10]. 
 
Determination of biochemical parameters 
 
After the mice were anaesthetised with diethyl 
ether, the eyeballs were removed with tweezers. 
Next, 1.5 mL of blood was collected using a 
sterile blood collection tube and centrifuged at 
(5,000 revolutions/min at a centrifugal radius of 6 
cm for 10 min, and serum was recovered. An 
automatic biochemical analyser was used to 
measure levels of alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST). 
Liver tissues were collected, washed with normal 
saline at 4°C, and dried with filter paper. 
Samples (0.2 g) of liver tissues were taken and 
10 % (w/v) homogenates were prepared, and 
centrifuged at 4,500 revolutions/min at a 
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centrifugal radius of 6 cm for 10 min. The 
supernatants were removed and the levels of 
MDA, SOD, TNF-α, and IL-6 measured following 





Analyses were conducted using SPSS version 
20.0. Data are expressed as means ± standard 
deviation (SD). Enumerated data were assessed 
using χ2 tests, whereas categorical data were 
processed using t-tests. P < 0.05 was taken to 




Serum ALT and AST levels  
 
The serum ALT and AST levels of the test group 
were significantly higher than those of the control 
group (both p < 0.05), indicating that the animal 
model had been established successfully. The 
serum ALT and AST levels of the bifendate and 
Qizhuyigan groups were much lower than those 
of the test group (both p < 0.05). The ALT and 
AST levels were lowest in the Qizhuyigan group 
(Table 1).  
 
Table 1: Serum ALT and AST levels in the various 
groups (mean ± SD, U/L, N = 30) 
 
Group ALT AST 
Control 43.10±6.30 98.40±10.40 
Test 224.70±18.40* 362.60±16.60* 




* p < 0.05 compared with that of the blank control 
group; #  p < 0.05 compared with that of the test group 
 
MDA and SOD contents of liver homogenates  
 
Compared with the control, SOD levels in the 
hepatic tissue homogenate of the test group 
decreased, but MDA levels increased (p < 0.05), 
indicating peroxidation damage. Compared with 
the bifendate group, the Qizhuyigan group 
exhibited clearly reduced MDA levels in hepatic 
tissue homogenate (p < 0.05) and increased 
SOD levels (p < 0.05). MDA and SOD contents 
changed the most in the Qizhuyigan group, 
indicating that Qizhuyigan enhanced anti-
lipid peroxidation ability (Table 2).  
 
TNF-α and IL-6 contents of liver homogenates  
 
Compared with the control group, the TNF-α and 
IL-6 levels in the liver homogenate of the test 
group were significantly increased (both p < 
0.05), indicating more serious damage to liver 
tissues in the former group. Compared with the 
test group, the bifendate group and the 
Qizhuyigan group exhibited significantly reduced 
TNF-α and IL-6 levels (both p values < 0.05); this 
was especially true of the Qizhuyigan group, 
suggesting that the anti-hepatic injuryability of 
Qizhuyigan may be related to inhibition of the 
release of the cytotoxic factors TNF-α and IL-6 
(Table 3).  
 
Table 2: MDA and SOD contents of liver 
homogenates of the groups (mean ± SD, N = 30) 
 
Group MDA (μmol/L) SOD (U/g) 
Control 4.70±1.40 33.70±4.70 
Test 31.30±6.60* 10.20± 2.40* 




* p < 0.05 compared with the blank control group; # p < 
0.05 compared with the test group 
 
Table 3: Comparison of TNF-α and IL-6 contents in 
liver homogenates of the various groups (mean ± SD, 
ng/L, N = 30) 
 
Group TNF-α IL-6 
Control 112.90±21.70 53.20±12.70 
Test 364.90±40.90* 229.20±33.90* 




* p < 0.05 compared with the blank control group; # p < 




Viral hepatitis is a relatively common infectious 
disease. The occurrence of immunoreactions in 
the liver is an important factor causing liver 
injuries in patients with viral hepatitis. Currently, 
effective drugs for treating chronic viral hepatitis 
are lacking, but good curative effect may be 
achieved if the treatment is focused on regulating 
immunity. The occurrence of liver injury in 
patients with chronic viral hepatitis appears to be 
significantly correlated with immune dysfunction 
and immunodeficiency [11]. The animal model of 
immunological liver injury used in this study was 
associated with extensive cytokine release (e.g., 
TNF-α and IL-6) and oxygen radicals, similar to 
the pathogenesis of liver injury induced by 
chronic viral hepatitis. Thus, the mouse model 
was suitable for the purpose [12]. 
 
Traditional Chinese medicine suggests that liver 
injury is caused by insufficient anti-pathogenic 
energy, damp-heat, and pestilent toxin. The 
basic therapies used to treat Chronic Hepatitis B 
(CHB) are based on toxin elimination, phlegm 
reduction, relief of fatigue, correction of 
deficiencies, and tonification. Traditional Chinese 
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medicine can help treat various difficult diseases, 
and scholars are focusing on applying traditional 
Chinese medicine to develop drugs to treat liver 
diseases. 
 
The Qizhuyigan capsule used in this study was 
developed based on clinical experience using 
traditional Chinese medicine to treat viral 
hepatitis, along with features of traditional 
Chinese medicine, such as diagnosis and 
treatment based on an overall analysis of the 
illness and the patient's condition, as well as 
modern pharmacology. The capsule consists of 
seven traditional Chinese medicine materials, 
including the root of red-rooted salvia, felwort, 
white atractylodes rhizome, Astragalus 
membranaceus, and radix isatidis. Astragalus 
membranaceus is frequently used in traditional 
Chinese medicine, with effects such as tonifying 
qi, lifting yang, strengthening the exterior, 
reducing sweat, inducing diuresis to alleviate 
oedema, and promoting fluid and blood 
production. Work using modern pharmacological 
techniques [13,14] has revealed that Astragalus 
membranaceus contains active ingredients, such 
as astragaloside, which can improve cardio-
pulmonary function, enhance immunity and 
promote the body’s resistance to disease, 
specifically its ability to resist viruses. 
 
ALT and AST levels can directly reflect the 
degree of liver injury. Previous research has 
found that damage to 1 % of hepatocytes can 
double the levels of ALT and AST in the liver 
[15]. Levels of ALT and AST in the test group 
were clearly increased compared with the blank 
control group, and those in the bifendate and 
Qizhuyigan groups were significantly decreased, 
indicating that Qizhuyigan had a protective effect 
in this mouse model of immunological liver injury. 
 
Lipid peroxidation plays an important role in the 
occurrence and development of immunological 
liver injury. MDA is the end product of 
lipid peroxidation, the content of which is 
positively proportional to the degree of lipid 
peroxidation [16].  
 
SOD is important in balancing oxidant and 
antioxidant content in the body, and can remove 
superoxide anion free radicals and protect cells 
from damage [17]. Thus, levels of SOD and MDA 
can reflect the degree of damage caused by 
peroxidation. Our results indicate that Qizhuyigan 
can significantly lower MDA and increase SOD in 
mice, indicating positive anti-lipid peroxidation 
effects. 
 
TNF-α not only directly kills hepatocytes, but also 
promotes liver injury [18]. IL-6 has functions in 
regulating immunoresponses and promoting the 
growth of hepatocytes [19]. The results of this 
study suggest that Qizhuyigan may effectively 
protect the liver by significantly lowering TNF-α 
and IL-6 content and reducing the release of 




Qizhuyigan protected mouse liver function in 
animals with induced immunological liver injury. 
The mechanism of action appeared to be related 
primarily to the inhibition of immune function and 
lipid peroxidation in the liver, thereby providing 
some theoretical pharmacological foundation for 
the clinical treatment of chronic viral hepatitis 
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